Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.55 |
| ▸ | ABL1 | P00519 | 5/20 | 0.53 |
| ▸ | BCR | P11274 | 5/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.48 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4235267 | 0.96 | AURKA (0.55) | AURKAABL1BCRKDRTHRB | |
| SCHEMBL4234991 | 0.85 | THRB (0.54) | KDRTHRBEGFRTNNI3KERBB4 | |
| SCHEMBL4239038 | 0.84 | AURKA (0.70) | AURKAABL1BCRTHRBEGFR | |
| SCHEMBL4235274 | 0.83 | THRB (0.57) | AURKAKDRTHRBEGFRTNNI3K | |
| SCHEMBL13777940 | 0.81 | EGFR (0.74) | AURKAKDRTHRBEGFRERBB4 | |
| SCHEMBL13777945 | 0.79 | EGFR (0.74) | AURKAKDRTHRBEGFRERBB4 | |
| SCHEMBL4239378 | 0.76 | ABL1 (0.69) | AURKAABL1BCRKDRTNNI3K | |
| SCHEMBL4108901 | 0.72 | ABL1 (0.58) | ABL1BCRTHRBKDM4EMAPT | |
| SCHEMBL690595 | 0.71 | EGFR (0.55) | KDRTHRBEGFRTNNI3KMAPT | |
| SCHEMBL4237476 | 0.71 | AURKA (1.00) | AURKASYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | claimed |
| EP-1943233-A2 | COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2008-07-16 | — | — | EP | claimed |
| WO-2007056151-A2 | PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | claimed |
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC | 2009-07-16 | — | — | US | disclosed |
| EP-1943233-A2 | COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS | IRM, LLC (BM) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007056151-A2 | PROTEIN KINASE INHBITORS | IRM LLC (BM) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181991-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ERBB2, BMX, ERBB3 | AURKA 43/4885ABL1 75/4885BCR 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.